| Company (Symbol) | Partner | Amount (M) | Trigerring Event | Details/Date |
| JANUARY | ||||
| AVANT Immunotherapeutics Inc. (AVNT) | Novartis Pharma AG | $6 | Exercise of license option | AVANT received $6M when Novartis exercised a license option for use of TP10 in the field of transplantation (1/13) |
| ImClone Systems Inc. (IMCL) | Merck KGaA | $4 | Preparation and delivery of regulatory document | ImcClone received $4M payment for delivering to Merck a regulatory document for its submission for a Phase II study of IMC-C225 in Spain in patients with refractory advanced squamous cell head and neck carcinoma (1/12) |
| The Immune Response Corp. (IMNR) | Agouron Pharmaceuticals (wholly owned subsidiary of WarnerLambert Co.; NYSE: WLA) | $5 | Quarterly payment | Immune Response received the last of six quarterly payments of $5M paid under terms of collaboration for Remune HIV therapy; the $5M payment consists of a $3M payment for clinical and manufacturing development expenses and $2M for the purchase of 0.27M shares of common stock (1/18) |
| Ligand Pharmaceuticals Inc. (LGND) | Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Porducts Corp.; NYSE:AHP) | ND | Selection of development candidate | Ligand received undisclosed milestone as a result of AHP declaring the compound WAY160910, a non-steroidal progesterone antagonist, a development candidate (1/4) |
| Ontogen Corp.* | Novo Nordisk A/S (NYSE:NVO) | ND | Compound discovery | Ontogen received undisclosed equity investment for identifying novel smallmolecule inhibitors of protein tyrosine phosphatase 1B (1/25) |
| Pharmacopeia Inc. (PCOP) | Schering AG | ND | Lead compound identification | Pharmacopeia received undisclosed milestone payment for identifying a lead compound that met potency and other selectivity criteria in lead discovery services agreement with Schering (1/13) |
| Pharmacyclics Inc. (PCYC) | Alcon Pharmaceuticals Ltd. | ND | Clinical trial results | Pharmacyclics received undisclosed milestone payment based on results of ongoing Phase II trial of Optrin photodynamic therapy for age-related macular degeneration (1/10) |
| Vical Inc. (VICL) | Merck & Co. Inc. (NYSE:MRK) | $1 | Initiation of clinical trial | Vical received $1M upon Merck s initiation of a Phase I clinical trial testing a naked DNA vaccine for HIV (1/7) |
| Vivus Inc. (VVUS) | AstraZeneca plc (NYSE:AZN) | $2 | Marketing approval | Vivus received $2M for Italian marketing approval for Muse (alprostadil, an erectile dysfunction therapy) (1/4) |
| FEBRUARY | ||||
| Aquila Biopharmaceuticals Inc. (AQLA) | Progenics Pharmaceuticals Inc. (PGNX) and Bristol-Myers Squibb Co. (NYSE:BMY) | ND | ND | Aquila received a milestone payment in connection with use of its Stimulon adjuvant QS-21 in a cancer vaccine program (2/14) |
| Aquila Biopharmaceuticals Inc. (AQLA) | Neuralab Ltd. (wholly owned subsidiary of Elan Corp. plc (NYSE:ELN) | ND | ND | Aquila received a milestone payment in connection with the use of its Stimulon adjuvant QS-21 with an undisclosed antigen in the field of Alzheimer s disease (2/14) |
| Aviron (AVIR) | Wyeth Lederle Vaccines (business unit of Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corp. [NYSE:AHP]) | $2 | Equity investment | Wyeth purchased 0.103M shares of Aviron common stock at $19.36 per share for an aggregate of $2M (2/3) |
| BioCryst Pharmaceuticals Inc. (BCRX) | R.W. Johnson Pharmaceutical Research Institute (subsidiary of Johnson & Johnson [NYSE:JNJ]) | $4 | Initiation of clinical trial | BioCryst received a $4M milestone payment under 9/98 agreement for the initiation of Phase III clinical trials of RWJ-27021 (BCX-1812), an oral influenza neuraminidase inhibitor, in North America and Europe (2/8) |
| Cell Genesys Inc. (CEGE) | Aventis Pharmaceuticals (pharmaceutical arm of Aventis SA [NYSE:AVE]) | $2 | Licensing anniversary | Cell Genesys received $2M payment in connection with anniversary of 1997 licensing agreement for gene activation technology for gene-activated erythropoietin and a second undisclosed protein (2/2) |
| Cytoclonal Pharmaceutics Inc. (CYPH) | Bristol-Myers Squibb Co. (NYSE:BMY) | ND | ND | Cytoclonal received an undisclosed payment under 1998 agreement to develop paclitaxel production methods using fermentation and genetic engineering (2/23) |
| Genzyme Molecular Oncology (GZMO) | Separate agreements with Schering-Plough Corp. (NYSE:SGP) and Warner-Lambert Co. (NYSE:WLA) | $3 | Clinical trial advance and licensing fee | Genzyme Molecular received a total of $3M through a milestone payment from Schering-Plough, which advanced a p53 tumor supressor gene in ovarian cancer trials, and renewal of a licensing fee from Warner-Lambert for access to Genzyme Molecular s SAGE (Serial Analysis of Gene Expression) database (2/7) |
| Neurocrine Biosciences Inc. (NBIX) | Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Products Corp. [NYSE:AHP]) | $1.50 | Target validation and small-molecule discovery | Neurocrine received $1.5M for moving 3/99 collaboration forward in smallmolecule identification and target validation for two separate targets (1/31) |
| Paradigm Genetics Inc. (PDGM) | Bayer AG (OTC BB:BAYZY) | ND | Delivery of assay and bioinformatics system | Paradigm received undisclosed milestone payment for delivery of an assay for high-throughput screening and of release 1.1 of a customized FunctionFinder bioinformatics system for discovery of herbicide targets (2/23) |
| Unigene Laboratories Inc. (OTC BB:UGNE) | Warner-Lambert Co. (NYSE:WLA) | $1 | Clinical supplies testing | Unigene completed testing of clinical supplies of oral calcitonin that will be used by Warner-Lambert in an upcoming Phase I/II trial (2/25) |
| MARCH | ||||
| Angiotech Pharmaceuticals Inc. (ANPI) | Boston Scientific Corp. (NYSE: BSX) | C$1.8 (US$1.23) | Regulatory filing | Under terms of 7/97 agreement, Angiotech received a $1.8M milestone payment triggered by a filing to initiate clinical studies of a paclitaxelcoated coronary stent for treating restenosis associated with stent implantation (3/10) |
| Biohybrid Inc.* | Micromet GmbH* | ND | ND | Biohybrid received a milestone under 12/99 licensing agreement for Biohybrid's Activating Hybrid Anbody (3/28) |
| Connetics Corp. (CNCT) | Celltech Group plc (LSE:CTH) | $5 | Manufacturing scale-up | Under 1/99 agreement with Medeva plc (since merged with Celltech), Connetics received a $5M payment for completion of manufacturing scale-up of ConXn (recombinant human relaxin) from pilot lots to commercial quantities (3/20) |
| Genset SA (GENXY) | Abbott Laboratories (NYSE: ABT) | $10 | Exercise of put option | Genset exercised a put option under 7/99 agreement to issue the equivalent of $10M worth of Genset equity to Abbott; the exercise will result in the issuance and sale of 0.055M ordinary shares at about $178 per share (3/15) |
| ImClone Systems Inc. (IMCL) | Merck KGaA | $2 | Expansion of clinical trial | Under terms of longstanding collaboration, ImClone receives a milestone of $2M for expansion into France of a Phase II study combining IMC225 and cisplatin to treat refractory advanced squamous cell head and neck carcinoma (3/15) |
| Inflazyme Pharmaceuticals Ltd. (CDNX: IZP) | Aventis Pharma (the pharmaceutical company of Aventis SA; NYSE:AVE) | C$5.82 (US$3.94) | Equity purchase | Aventis bought C$5.82M (US$3.94M) of Inflazyme equity under 2/99 agreement (3/20) |
| NeoPharm Inc. (AMEX:NEO) | Pharmacia & Upjohn (NYSE: PNU) | $3 | Clinical trial progress | NeoPharm received a $3M milestone for completing Phase I and beginning Phase II clinical trials for liposomal-encapsulated paclitaxel (3/15) |
| Organogenesis Inc. (AMEX: ORG) | Novartis Pharma AG | $5 | Regulatory progress | Organogenesis received $5M in advance due to submission of PMA supplement for Apligraf (3/24) |
| APRIL | ||||
| Avax Technologies Inc. (AVXT) | Australian Vaccine Technologies Ltd. (Formerly Neptunus International Holdings Ltd.) | A$3 (US$1.8) | Exercise of equity option | AVT invested an additional A$3M (US$1.8) in the companies joint venture, Avax Australia Pty. Ltd. (4/6) |
| Corixa Corp. (CRXA) | NV Organon | $1 | Clinical trial completion | Corixa received a $1M milestone payment following the completion of a Phase I/II trial of AnergiX.RA complex for rheumatoid arthritis (4/17) |
| CV Therapeutics Inc. (CVTX) | Biogen Inc. (BGEN) | $6.50 | Continued development of product | CV received a $6.5M milestone, consisting of $2M in cash and a $4.5M line of credit; the milestone was paid in connection with Biogen s decision to continue with the adenosine A1 receptor antagonist program for congestive heart failure following completion of a Phase II trial of CVT-124 (4/10) |
| Exelixis Inc. (EXEL) | Pharmacia Corp. (NYSE:PHA) | ND | Delivery of novel drug targets | Exelixis delivered two novel drug targets to Pharmacia under 2/99 agreement, bringing the total number of targets delivered to three (4/23) |
| Guilford Pharmaceuticals Inc. (GLFD) | Aventis SA (NYSE:AVE) | $1 | Regulatory approval | Guilford received $1M for regulatory approval of Gliadel Wafer in Spain for use as an adjunct to surgery to prolong survival in patients with glioblastoma multiforme (4/11) |
| Isis Pharmaceuticals Inc. (ISIP) | Elan Corp. plc (NYSE:ELN) | $7.50 | Equity purchase | Elan purchased 0.3M shares of Isis common stock at $25.50 per share for a total of $7.5M under a joint-venture agreement initiated 1/00 (4/12) |
| Paradigm Genetics Inc. (PDGM) | Bayer AG | ND | Delivery of high-throughput screening assay | Paradigm delivered an assay under 10/98 agreement to develop novel herbicide screening targets |
| Unigene Laboratories Inc. (OTC BB: UGNE) May | Warner-Lambert Co. (NYSE:WLA) | $3.50 | Initiation of clinical trial | Warner-Lambert initiated Phase I/II trial of an oral calcitonin product developed by the two companies and paid Unigene a $3.5M milestone (4/12) |
| MAY | ||||
| Amrad Corp. Ltd. (ASX:AML) | Baxter Healthcare Corp. (NYSE:BAX) | $2 | Production milestone | Amrad received $2M under 3/99 agreement for producing significant quantities of vascular endothelial growth factor B protein (AM133) |
| Cortex Pharmaceuticals Inc. (OTC BB: CORX) | NV Organon | $2 | Selection of clinical candidate | Cortex received $2M under 1/99 agree ment upon selection of an Ampakine drug candidate to enter Phase I trials (5/9) |
| NiCox SA (Nouveau Marche:NICOX) | AstraZeneca plc (NYSE:AZN) | $2 | Initiation of clinical trial | NicOx received $2M under 1998 agreement upon AstraZeneca's start of Phase I trial of HCT-3012, a pain and inflammation drug (5/19) |
| NPS Pharmaceuticals Inc. (NPSP) | Janssen Pharmaceutica NV (subsidiary of Johnson & Johnson [NYSE:JNJ]) | $2 | ND/equity purchase | NPS satisfied conditions under 10/98 agreement for equity purchase by Johnson & Johnson Development Corp.; original agreement was signed with Allelix Biopharmaceuticals, now a NPS subsidiary (5/11) |
| Onyx Pharmaceuticals Inc. (ONXX) | Warner-Lambert Co. (NYSE:WLA) | $3.70 | Feasibility demonstration | Onyx received $3.7M for demonstrating the feasibility of using a selectively replicating adenovirus to deliver an anticancer gene (5/23) |
| Paradigm Genetics Inc. (PDGM) | Pharmacia Corp. (NYSE:PHA) | ND | ND | Paradigm received an undisclosed milestone payment under 1/00 functional genomics agreement (5/18) |
| Regeneron Pharmaceuticals Inc. (REGN) | Sumitomo Pharmaceutical Co. | $3 | ND | Regeneron received $3M payment (less $0.3M for Japanese tax) related to development of brain-derived neurotrophic factor in Japan (5/2) |
| Vertex Pharmaceuticals Inc. (VRTX) | Aventis SA | $10 | ND | Vertex received $10M payment under 9/93 agreement (expanded 9/99) to develop HMR 3480/VX-740 and other compounds for a range of inflammatory diseases; original agreement was with Hoechst Marion Roussel, since merged with Rhone-Poulenc to form Aventis (5/24) |
| JUNE | ||||
| Elan Corp. plc (NYSE:ELN) | Ligand Pharmaceuticals Inc. (LGND) | $4 | Submission of new drug application to the FDA | Ligand will issue 0.367M shares to Elan at $10.89 per share (average closing price for five days prior to milestone achievement) for a total of $4M; Elan will now own 12.5% of Ligand (6/8) |
| Emisphere Technologies Inc. (EMIS) | Eli Lilly and Co. (NYSE:LLY) | $2 | Initiation of development collaboration | Emisphere received a $2M milestone under terms of 1997 research and option agreement upon execution of follow-on development agreement for oral formulations of Forteo (recombinant parathyroid hormone) and Humatrope (6/13) |
| GenVec Inc.* | Parke-Davis Pharmaceutical Division of Warner-Lambert Co. (now merged with Pfizer Inc.; NYSE:PFE) | $2 | Development of manufacturing technology | GenVec received a $2M milestone for development of manufacturing technology for the Biobypass angiogenic agent, a therapy for the treatment of coronary artery disease and peripheral vascular disease (6/6) |
| Myriad Genetics Inc. (MYGN) | Schering-Plough Corp. (NYSE:SGP) | $1 | Gene discovery | Myriad discovered a prostate cancer susceptibility gene, which resulted in a $1M payment from Schering-Plough under terms of 1997 research collaboration (6/6) |
| NaPro BioTherapeutics Inc. (NPRO) | Abbott Laboratories (NYSE:ABT) | $4 | Equity investment triggered by undisclosed event | NaPro received $4M in the form of cash for 0.711M shares of common stock at $5.625 per share under agreement for development of NaPro paclitaxel in the U.S. (6/28) |
| Novazyme Pharmaceuticals Inc.* | Neose Technologies (NTEC) | ND | Neose invested in Novazyme convertible debentures (6/12) | |
| PowderJect Pharmaceuticals plc (LSE:PJP) | Serono (SWX:SEO) | 1 (US$1.5) | Advancement of product into clinical development | Following successful completion of initial testing, companies decided to progress development of Gonal-F (recombinant folliclestimulating hormone) delivered via PowderJect system into clinical development; decision triggered a 1M (US$1.51M) milestone (6/12) |
| Regeneron Pharmaceuticals Inc. (REGN) | The Procter & Gamble Co. (NYSE:PG) | $17 | Equity investment under collaboration agreement | P&G purchased 0.574M shares at $29.75 per share pursuant to 1997 agreement granting Regeneron the right to sell $17M worth of stock; the price is the same price per share as Regeneron's 4/00 public offering; P&G now owns about 16% of Regeneron (6/1) |
| Shearwater Polymers Inc.* | F. HoffmannLa Roche Ltd. | $1 | Regulatory filing | Shearwater received $1M milestone payment when Roche filed a new drug application for Pegasys, a pegylated formulation of interferon (6/5) |
| Synsorb Biotech Inc. (SYBB) | MDS Sciex (TSE:MDS) | ND | Patent issuance | Synsorb received a milestone payment upon issuance of the first of several key high-throughput screening patents for INH Technologies Inc., a former subsidiary Synsorb sold to MDS 3/00 (6/27) |
| Transgene (TRGNY) | Schering-Plough Corp. (NYSE:SGP) | $1 | Preclinical success | Animal studies at Canji Inc. (the gene therapy center for ScheringPlough Research Institute) demonstrated that Transgene's new adenoviral vector was safer than firstgeneration adenovirus vectors when used to deliver the p53 tumorsuppressor gene (6/8) |
| JULY | ||||
| Millennium Pharmaceuticals Inc. (MLNM) | Aventis Pharma (unit of Aventis SA; NYSE:AVE) | $150 | End of HartScott-Rodino waiting period | Companies received notice from the U.S. Federal Trade Commission of early termination of the waiting period under the HartScott-Rodino Antitrust Improvements Act of 1976, allowing collaboration to move forward (7/28) |
| Ribozyme Pharmaceuticals Inc. (RZYM) | Eli Lilly and Co. (NYSE:LLY) | $1 | Clinical development milestone | Lilly made a $1M milestone payment to Ribozyme as a result of meeting a clinical development goal with the anti-hepatitis C ribozyme LY 466700 (7/21) |
| AUGUST | ||||
| Avax Technologies Inc. (AVXT) | Australian Vaccine Technologies Ltd. | $3 | Equity purchase | Avax Technologies Australian joint venture, Avax Australia Pty. Ltd., received $3M from the joint venture s partner, Australian Vaccine; this is the final payment in investments totaling $10M for a 50 percent interest in Avax Australia (8/23) |
| DeCode Genetics Inc. (DCGN) | F. HoffmannLa Roche Ltd. | ND | Development milestone | DeCode scientists mapped a novel gene that contributes to the occurrence of the common form of Alzheimer s disease; DeCode received an undisclosed milestone payment (8/18) |
| Enchira Biotechnology (ENBC) | Genencor International Inc. (GCOR) | $1 | Follow-on agreement | Genencor will provide $1M of funding to Enchira over the next two years as part of a follow-on to a licensing agreement made in May, under which Genencor gained access to Enchira s technology to develop gene-based products (8/28) |
| Exelixis Inc. (EXEL) | Genoptera LLC* | ND | Development milestone | Genoptera, a joint venture between Exelixis and Bayer AG, selected several novel insecticide targets for assay development and screening, triggering an undisclosed milestone payment to Exelixis (8/10) |
| Paradigm Genetics Inc. (PDGM) | Pharmacia Corp. (NYSE:PHA) | ND | Development milestone | Paradigm exceeded milestones in a functional genomics collaboration with Pharmacia by delivering 20 percent more gene function data than required, triggering an undisclosed milestone payment (8/21) |
| Phylos Inc.* | Amgen Inc. (AMGN) | ND | Development milestone | Phylos reached milestones in its collaboration with Amgen to identify high-affinity binding agents to potential therapeutic targets; financial details of the achievement were not disclosed (8/24) |
| Rosetta Inpharmatics Inc. (RSTA) | Agilent Technologies Inc. (NYSE:A) | $10 | IPO | Agilent invested $10M in Rosetta through a private placement concurrent with Rosetta s IPO |
| Targeted Genetics Corp. (TGEN) | Elan Corp. plc (NYSE:ELN) | $5 | Investment agreement | Elan agreed to make a $5M equity investment in July 1999 when a joint venture was established, and Elan agreed to an additional $5M investment on the one-year anniversary date of the agreement; the 382,739 issued shares were priced at a premium to Targeted s average closing share price (8/16) |
| SEPTEMBER | ||||
| Arena Pharmaceuticals Inc. (ARNA) | Eli Lilly & Co. (NYSE:LLY) | ND | Research milestone | Arena received its first research milestone payment from Lilly related to Lilly s acceptance of CART-activated versions of three G protein-coupled receptors (9/25) |
| Compugen Ltd. (CGEN) | Pfizer Global Research and Development (NYSE:PFE) | ND | Development milestone | Compugen identified predicted genes through clustering and assembly of genomic DNA and cDNA sequences as part of a 1998 multiyear agreement with Warner-Lambert Co., which has been acquired by Pfizer Inc. (9/13) |
| ImmunoGen Inc. (IMGN) | SmithKline Beecham plc | $2 | Development milestone | Company received a $2M payment from SmithKline for entering a second Phase I/II trial for huC242-DM1/SB-408075 (9/21) |
| Interneuron Pharmaceuticals Inc. (IPIC) | Pfizer Inc. | $3 | Development milestone | Interneuron announced it would receive a $3M payment from Pfizer for the initiation of clinical trials checking the safety and efficacy of pagoclone for use in panic disorder (9/12) |
| Iomai Corp.* | Mitsubishi Corp. | US$2 | Equity investment | A wholly owned subsidiary of Mitsubishi made the investment, the first direct investment by Japanese interests in Iomai (9/5) Applied Biosystems made the equity investment in Genomica at the same time |
| Genomica Corp.* | Applied Biosystems (formerly P.E. Biosystems [NYSE:PEB]) | $3 | Equity investment the two companies formed a technology | license agreement (9/6) |
| MorphoSys AG (Neuer Markt:MOR) | GPC Biotech AG (Neuer Markt:GPC) | ND | Development milestone | MorphoSys received a milestone payment for developing high-affinity antibodies in its immunology collaboration with GPC (9/25) |
| OCTOBER | ||||
| Abgenix Inc. (ABGX) | Pfizer Inc. (NYSE:PFE) | ND | Regulatory milestone | Abgenix received an undisclosed milestone payment for filing an IND application for a fully human monoclonal antibody product candidate to treat cancer, which was generated with Abgenix s XenoMouse technology (10/2) |
| Alkermes Inc. (ALKS) | Amylin Pharmaceuticals Inc. (AMLN) | $0.50 | Development milestone | Amylin made a milestone payment to Alkermes of $500,000 for the completion of the feasibility stage of their collaboration for the development of an injectable long-acting release formulation of AC2993 to treat Type II diabetes (10/17) |
| Arena Pharmaceuticals Inc. (ARNA) | Taisho Pharmaceutical Co. Ltd. | ND | Development milestone | Arena has achieved several financial research and development milestones related to acceptance by Taisho of a CART-activated version of a G protein-coupled receptor target and a request that Arena screen the receptor using Arena s in-house chemical library (10/23) |
| Aviron (AVIR) | SmithKline Beecham Biologicals (NYSE:SBH) | $1.50 | Development milestone | Aviron received a $1.5M milestone payment as a result of the start of a Phase II trial to investigate a vaccine against the EpsteinBarr virus (10/25) |
| Chronix Biomedical* | Hemispherx Biopharma Inc. (AMEX:HEB) | ND | Equity investment | Hemispherx completed an equity investment in Chronix as part of their alliance on the development of new diagnostic products for the various stages of gene reshuffling (10/31) |
| Cubist Pharmaceuticals Inc. (CBST) | Novartis Pharma AG (NYSE:NVS) | $0.50 | Discovery milestone | Cubist will receive a $500,000 milestone payment for the delivery of a validated target and a high-throughput screening assay for anti-infective drug discovery in its collaboration with Novartis (10/3) |
| DeCode Genetics Inc. (DCGN) | F. HoffmannLa Roche Ltd. | ND | Discovery milestone | DeCode scientists and Icelandic psychiatrists identified a gene linked to schizophrenia (10/20) |
| HiberGen Ltd.* | Trinity Biotech plc (TRIBY) | $1.30 | Equity investment | Trinity Biotech acquired 33.3% of the share capital of HiberGen for a consideration of $1.3M (10/5) |
| Integra LifeSciences Holdings Corp. (IART) | Ethicon Inc. (a Johnson & Johnson Co.) | $0.75 | Clinical and research milestone | Integra received $750,000 in connection with the completion of one of the clinical and research payment events under the strategic alliance for Integra Dermal Regeneration Template (10/13) |
| Ligand Pharmaceuticals Inc. (LGND) | Eli Lilly & Co. (NYSE:LLY) | ND | Discovery milestone | Ligand received undisclosed milestone payments from Lilly as LY510929 and a backup compound were declared clinical candidates for Type II diabetes and cardiovascular disease (10/4) |
| MediciNova Inc.* | Tanabe Seiyaku Co. Ltd. | $5 | Equity investment | MediciNova received its first $5M equity investment from Tanabe, which has committed an additional $5M investment within one year (10/6) |
| Pharmasset Ltd.* | DuPont Pharmaceuticals Co. (NYSE:DD) | ND | Equity investment | The investment, about one year after the initiation of a research collaboration between the companies, increases DuPont s ownership in Pharmasset from 1.7% to about 2.2% (10/10) |
| Unigene Laboratories Inc. (OTC BB:UGNE) | Pfizer Inc. (NYSE:PFE) | ND | Development milestone | Unigene received a milestone payment from Pfizer associated with the ongoing clinical studies for its oral calcitonin program (10/26) |
| Vertex Pharmaceuticals Inc. (VRTX) | Glaxo Wellcome plc (NYSE:GLX) | $3 | Milestone | Vertex will receive a $3M milestone payment in the fourth quarter for European approval to market Agenerase for HIV (10/23) |
| ViroPharma Inc. (VPHM) | American Home Products Corp. (NYSE:AHP) | $6 | Milestone equity investment | ViroPharma sold 96,059 shares for $3M to American Home Products as a result of progress made under the companies hepatitis C virus collaboration; the price per share was based on a premium to a trailing average price (10/6); ViroPharma announced it sold an additional 104,934 shares for $3M as a result of further progress made under the collaboration (10/24) |
| NOVEMBER | ||||
| Avanir Pharmaceuticals Inc. (AMEX:AVN) | SmithKline Beecham Consumer Healthcare (NYSE:SBH) | $5 | Milestone payment | Avanir received a milestone payment for the initiation of the distribution of Abreva at the wholesale level (11/30) |
| Exelixis Inc. (EXEL) | Bayer AG | ND | Milestone payment | Genoptera LLC, a joint venture between Bayer and Exelixis, delivered several novel insecticide targets for assay development and screening to Bayer, triggering undisclosed milestone payments to Exelixis (11/15) |
| Neurobiological Technologies Inc. (NTII) | Merz & Co. | $2.50 | Up-front payment | Neurobiological Technologies received a $2.5M payment from Merz relating to Memantine; the payment is triggered by monies received by Merz pursuant to agreements between Merz and Forest Laboratories Inc. and A/S Lundbeck (11/1) |
| Response Genetics Inc.* | Dianon Systems Inc.* | $1 | Equity investment | Dianon made an equity investment in Response in connection with a sales and distribution agreement for the Danenberg Tumor Profile chemotherapy guidance system (11/16) |
| Structural Bioinformatics* | IBM | ND | Equity investment | IBM made an unspecified equity investment in Structural Bioinformatics; the companies are collaborating to make protein structural databases more readily available to researchers on a subscription basis via the Internet (11/29) |
| Targeted Genetics Corp. (TGEN) | Celltech Group plc (LSE:CCH; NYSE:CLL) | $2 | Milestone payment | Targeted Genetics received a $2M milestone payment for starting a Phase II trial of tgAAV-CF for cystic fibrosis (11/17) |
| Versicor Inc. (VERS) | Novartis Pharma AG | ND | Milestone payment | Versicor achieved a second milestone in its three-year collaboration with Novartis, and will receive a second milestone payment for an assay, which has been implemented in Novartis high-throughput screening lab to identify new anti-infective drugs (11/15) |
| DECEMBER | ||||
| Aviron (AVIR) | American Home Products Corp. (NYSE:AHP) | $15.50 | Milestone payment | Aviron received a $15.5M payment for the FDA s acceptance of a BLA for FluMist (12/29) |
| Celgene Corp. (CELG) | Novartis Pharma AG | $5 | Milestone payment | Novartis paid Celgene $5M for the FDA s acceptance of the NDA for d-methylphenidate (12/27) |
| CeNeS Pharmaceuticals plc (LSE:CEN.L) | Shire Pharmaceuticals Group plc (SHPGY; LSE:SHP) | 0.5 (US$0.75) | Equity investment | Shire made an equity investment in CeNeS of 500,000 (12/20) |
| USA Pharmaceuticals Inc. (DUSA) | Schering AG | $15 | Milestone payment | USA received $15M from Schering, based on the companies November 1999 marketing, development and supply agreement (12/21) |
| Exelixis Inc. (EXEL) | Bayer AG | ND | Milestone payment | Exelixis delivered new assays for highthroughput screening to Bayer, triggering undisclosed milestone payments (12/8) |
| Infigen Inc.* | Novartis Pharma AG | $1 | Milestone payment | Infigen received a $1M milestone payment from Novartis Pharma for developing a reproducible nuclear transfer-based cloning system and producing several litters of pigs (12/19) |
| MorphoSys AG (Neuer Markt:MOR) | F. HoffmannLa Roche Ltd. | ND | Milestone payment | MorphoSys reached the first milestone in its collaboration on HuCAL-derived medications for the treatment of Alzheimer s disease (12/11) |
| Neurochem Inc. (TSE:NRM) | H. Lundbeck A/S | US$2.5 | Milestone and equity investment | Neurochem achieved a milestone for the advancement of an antiamyloid drug candidate to treat Alzheimer s disease, triggering a number of undisclosed payments, including an equity purchase of US$2.5M (12/5) |
| NPS Pharmaceuticals Inc. (NPSP) | SmithKline Beecham plc | $1 | Milestone payment | NPS earned a $1M milestone payment for the start of clinical testing with calcilytics to treat osteoporosis (12/12) |
| Paradigm Genetics Inc. (PDGM) | Monsanto Co. | ND | Milestone payment | Paradigm received a milestone payment in its agreement with Monsanto to determine the function of genes (12/4) |
| Paradigm Genetics Inc. (PDGM) | Bayer AG | ND | Milestone payments | Paradigm delivered new assays for highthroughput screening, triggering undisclosed milestone payments (12/5) |
| Structural Bioinformatics Inc.* | Quest Diagnostics Inc. (NYSE:DGX) | ND | Equity investment | Quest Diagnostics made an equity investment in Structural Bioinformatics (12/14) |
| Notes: * Denotes privately held company All stocks listed on the Nasdaq exchange unless otherwise noted. ASX = Australian Stock Exchange; CNDX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; SWX = Swiss Exchange; TSE = Toronto Stock Exchange | ||||
